表紙
市場調査レポート

1型糖尿病(若年性糖尿病):パイプライン製品の分析

Type-1 diabetes (Juvenile Diabetes) - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 232787
出版日 ページ情報 英文 639 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
1型糖尿病(若年性糖尿病):パイプライン製品の分析 Type-1 diabetes (Juvenile Diabetes) - Pipeline Review, H2 2015
出版日: 2015年12月31日 ページ情報: 英文 639 Pages
概要

1型糖尿病(T1D)とは、膵臓がインスリン()の生産を中断するという自己免疫疾患です。人体の免疫系が膵臓内部のインスリン生産細胞(β細胞)を攻撃・破壊することで発症します。主な疾病素質として、先天性疾患や家族歴、膵臓疾患、感染症などが挙げられています。主な徴候・症状には、深刻な渇きや頻繁な尿意、極度の空腹感、体重減少、倦怠感、いらつき、非日常的行動などが挙げられます。治療に際しては、生活習慣の改善や提起的な薬物療法が必要となります。

当レポートでは、世界各国での1型糖尿病(若年性糖尿病)治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

1型糖尿病(若年性糖尿病)の概要

治療薬の開発

  • 1型糖尿病向けパイプライン製品:概要
  • 1型糖尿病向けパイプライン製品:比較分析

各企業で開発中の1型糖尿病治療薬

大学/研究機関で研究中の1型糖尿病治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 不明確な段階にある製品

1型糖尿病治療薬:開発中の製品の一覧(企業別)

1型糖尿病治療薬:研究中の製品の一覧(大学/研究機関別)

1型糖尿病治療薬の開発に従事している企業

  • Alcon, Inc.
  • Johnson & Johnson
  • Boehringer Ingelheim GmbH
  • Osiris Therapeutics, Inc.
  • Sanofi
  • AstraZeneca PLC
  • Eli Lilly and Company
  • Inovio Pharmaceuticals, Inc.
  • MedImmune, LLC
  • 第一三共
  • Merck & Co., Inc.
  • AbGenomics International, Inc.
  • Novo Nordisk A/S
  • Generex Biotechnology Corporation
  • BioLineRx, Ltd.
  • キッセイ薬品工業
  • Pfizer Inc.
  • Cell Therapeutics, Inc.
  • Hadasit Medical Research Services & Development Ltd.
  • Biodel Inc.
  • MannKind Corporation
  • Halozyme Therapeutics, Inc.
  • Merck KGaA
  • Evotec AG
  • Karo Bio AB
  • Ligand Pharmaceuticals, Inc.
  • Opexa Therapeutics, Inc.
  • Compugen Ltd.
  • Oramed Pharmaceuticals, Inc.
  • Lexicon Pharmaceuticals, Inc.
  • Flamel Technologies S.A.
  • NeoStem, Inc.
  • Tolerx, Inc.
  • XOMA Corporation
  • Uni-Bio Science Group Ltd.
  • Kamada Ltd.
  • DiaMedica Inc.
  • Affimed Therapeutics AG
  • Axxam SpA
  • ActogeniX NV
  • Bayhill Therapeutics, Inc.
  • Argos Therapeutics, Inc.
  • Cellectis S.A.
  • Coronado Biosciences, Inc.
  • MacroGenics, Inc.
  • Diabetology Limited
  • EpiVax, Inc.
  • Kineta, Inc.
  • Andromeda Biotech Ltd.
  • AIM Therapeutics Inc.
  • Noxxon Pharma AG
  • Fate Therapeutics, Inc.
  • Immunocore Limited
  • Provid Pharmaceuticals, Inc.
  • ViaCyte, Inc.
  • Tolera Therapeutics, Inc.
  • Medistem, Inc.
  • Exsulin Corporation
  • Medestea Research & Production S.p.A.
  • NasVax Ltd.
  • レグイミューン
  • Adocia
  • Amunix, Inc.
  • S-Evans Biosciences, Inc.
  • NGM Biopharmaceuticals, Inc.
  • Selecta Biosciences, Inc.
  • Cebix Incorporated
  • RhinoCyte, Inc.
  • PharmaIN Corporation
  • Thermalin Diabetes Inc.
  • Hanmi Pharmaceuticals, Co. Ltd.
  • Dance Pharmaceuticals
  • Beta-Cell NV
  • MidaSol Therapeutics LP
  • Escape Therapeutics, Inc.
  • Kasiak Research Pvt. Ltd.
  • Toleranzia AB
  • Paras Biopharmaceuticals Finland Oy
  • SEKRIS Biomedical, Inc.

1型糖尿病:治療薬の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • インスリンデグルデク+インスリンアスパルト
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • ヒトインスリン
  • インスリンデグルデク
  • インスリングラグリンのバイオシミラー
  • インスリンデグルデク+インスリンアスパルト
  • インスリンデグルデク
  • Linjeta
  • テプリズマブ
  • DiaPep-277
  • ヒトインスリン
  • insulin peglispro
  • NN-1218
  • シクロスポリン+ランソプラゾール
  • インスリンU-300
  • インスリングラグリンのバイオシミラー
  • アナキンラ
  • α1-プロテイナーゼ阻害剤(ヒト)
  • dapagliflozin
  • BHT-3021
  • インスリンPH20
  • remestemcel-L
  • セクキヌマブ
  • sotagliflozin
  • empagliflozin
  • ORMD-0801
  • Diamyd
  • INGAPペプチド
  • ゲボキズマブ
  • BCGワクチン
  • アナログ・インスリン-PH20
  • アトルバスタチンカルシウム
  • アバタセプト
  • ヒトインスリン
  • BIOD-123
  • ヒトインスリン
  • ヒトインスリン+Cペプチド+プロインスリン
  • ヒトインスリン吸入剤
  • 1型糖尿病向け樹状細胞療法
  • リソフィリン
  • メグフィルグラスチム
  • α1アンチトリプシン
  • CBX-129801
  • ヒト用プロインスリン
  • 間葉系幹細胞(MenSC)の移植
  • オテリキシズマブ
  • FT-105
  • VGX-1027
  • DM-199
  • LY-2409021
  • NN-1218
  • ShK-186
  • NN-1953
  • 長期作用型ヒトインスリン
  • T細胞療法プログラム
  • BIOD-125
  • NN-1954
  • RGI-3100
  • PF-06342674
  • BIOD-238
  • BIOD-250
  • remogliflozin etabonate
  • LAI-287
  • インスリンリスプロ+インスリングラグリン
  • NN-1956
  • EVT-770
  • AbGn-168H
  • 1型糖尿病向け細胞治療
  • 単球由来幹細胞
  • AGS-010
  • AIM-501
  • rExendin-4
  • AFM-15
  • IC-1
  • LGD-6972
  • CGEN-15001
  • TSO
  • RGI-3010
  • 抗CD3経口免疫療法
  • HSP70ペプチド
  • カンナビジオール
  • Leukothera
  • PGC GLP-1
  • PGCベース・インスリン
  • FT-201
  • ERC-124
  • XMet-A
  • 1型糖尿病向けTregitopes
  • MesoStem
  • AS-605240
  • BL-9020
  • タウロウルソデオキシコール酸
  • 1型糖尿病・シェーグレン症候群向けT細胞療法
  • 1型糖尿病向けCD4・CD8標的抗体
  • PHIN-837
  • NOX-G-15
  • 1型糖尿病向けIL-7受容体拮抗用抗体
  • 糖尿病向け前駆細胞
  • ヒトインスリンのバイオシミラー
  • インスリングラグリンのバイオシミラー
  • Refacell-T1D
  • 1型糖尿病向け医薬品
  • S-961
  • BetaGRAFT
  • 中枢神経系・骨格筋・呼吸器・代謝異常向けC-Rel阻害用小分子
  • 免疫系・胃腸系・中枢神経系・代謝異常向けCRACチャネル遮断用小分子
  • AB-101
  • PBS-1101-1104
  • cSN-50
  • 膵臓島細胞
  • ぜん虫類由来ペプチド
  • MED-1101
  • MER-3001
  • Fc-α-1アンチトリプシン
  • BP-1001
  • BP-2001
  • 1型糖尿病向けNOシンターゼ阻害用小分子
  • 1型糖尿病向け小分子
  • インスリングラグリン
  • DM-365
  • 免疫毒素
  • PBS-1106
  • PBS-1105
  • ヒトproIsletペプチド
  • PB-3020
  • PB-3040
  • PB-3030
  • PB (MDT)-3010
  • 1型糖尿病向け小分子
  • FcAAT-3
  • FcAAT-2
  • NOX-G16
  • VC-01
  • Peptidotsインスリン
  • 1型糖尿病向け複合型モノクローナル抗体
  • SKRS-95
  • Modified Insulin Mimetopes
  • SP-16
  • CSN-501
  • BSN-302
  • NavacimTD
  • 自己免疫疾患向け医薬品
  • 1型糖尿病向けPPLC細胞療法
  • Ig-GAD2+骨髄幹細胞
  • Kv1.3ブロッカー
  • TOL-101
  • ImmTAC標的膵島細胞
  • Glucostem
  • DQ2/DQ8標的薬剤
  • AMX-583
  • 1型糖尿病向けワクチン
  • NURR-1受容体標的薬剤
  • β細胞再生プログラム
  • 代謝異常向けIAPP標的合成ペプチド
  • 1型糖尿病向け経口薬
  • 1型糖尿病向けワクチン
  • 超即効性インスリン・アナログ
  • 超熱安定性インスリン・アナログ
  • 肝臓選択的インスリン・アナログ
  • 1型・2型糖尿病向けLRH-1活性化用小分子
  • β細胞再生プログラム
  • INV-88
  • INV-17
  • 糖尿病向けGLUT2・CTLA4標的二重特異性抗体
  • 糖尿病向け幹細胞治療
  • ALM
  • TargetEEM向け医薬品
  • インスリングラグリンのバイオシミラー
  • RhinoCytes

1型糖尿病治療薬:パイプライン製品の最新動向

1型糖尿病治療薬:開発が休止状態の製品

1型糖尿病治療薬:開発が中止された製品

1型糖尿病関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース(全10件)

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7199IDB

Summary

Global Markets Direct's, 'Type-1 diabetes (Juvenile Diabetes) - Pipeline Review, H2 2015', provides an overview of the Type-1 diabetes (Juvenile Diabetes)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Type-1 diabetes (Juvenile Diabetes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type-1 diabetes (Juvenile Diabetes) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Type-1 diabetes (Juvenile Diabetes)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Type-1 diabetes (Juvenile Diabetes) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Type-1 diabetes (Juvenile Diabetes) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Type-1 diabetes (Juvenile Diabetes) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Type-1 diabetes (Juvenile Diabetes)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Type-1 diabetes (Juvenile Diabetes) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Type-1 diabetes (Juvenile Diabetes) Overview
  • Therapeutics Development
  • Type-1 diabetes (Juvenile Diabetes) - Therapeutics under Development by Companies
  • Type-1 diabetes (Juvenile Diabetes) - Therapeutics under Investigation by Universities/Institutes
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline Products Glance
  • Type-1 diabetes (Juvenile Diabetes) - Products under Development by Companies
  • Type-1 diabetes (Juvenile Diabetes) - Products under Investigation by Universities/Institutes
  • Type-1 diabetes (Juvenile Diabetes) - Companies Involved in Therapeutics Development
  • Type-1 diabetes (Juvenile Diabetes) - Therapeutics Assessment
  • Drug Profiles
  • Type-1 diabetes (Juvenile Diabetes) - Recent Pipeline Updates
  • Type-1 diabetes (Juvenile Diabetes) - Dormant Projects
  • Type-1 diabetes (Juvenile Diabetes) - Discontinued Products
  • Type-1 diabetes (Juvenile Diabetes) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Type-1 diabetes (Juvenile Diabetes), H2 2015
  • Number of Products under Development for Type-1 diabetes (Juvenile Diabetes) - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Development by Companies, H2 2015 (Contd..1)
  • Number of Products under Development by Companies, H2 2015 (Contd..2)
  • Number of Products under Development by Companies, H2 2015 (Contd..3)
  • Number of Products under Development by Companies, H2 2015 (Contd..4)
  • Number of Products under Development by Companies, H2 2015 (Contd..5)
  • Number of Products under Development by Companies, H2 2015 (Contd..6)
  • Number of Products under Development by Companies, H2 2015 (Contd..7)
  • Number of Products under Development by Companies, H2 2015 (Contd..8)
  • Number of Products under Development by Companies, H2 2015 (Contd..9)
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Development by Companies, H2 2015 (Contd..2)
  • Products under Development by Companies, H2 2015 (Contd..3)
  • Products under Development by Companies, H2 2015 (Contd..4)
  • Products under Development by Companies, H2 2015 (Contd..5)
  • Products under Development by Companies, H2 2015 (Contd..6)
  • Products under Development by Companies, H2 2015 (Contd..7)
  • Products under Development by Companies, H2 2015 (Contd..8)
  • Products under Development by Companies, H2 2015 (Contd..9)
  • Products under Development by Companies, H2 2015 (Contd..10)
  • Products under Development by Companies, H2 2015 (Contd..11)
  • Products under Development by Companies, H2 2015 (Contd..12)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by 4SC AG, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Adocia, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by AiCuris GmbH & Co. KG, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Ambrx, Inc., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by AntriaBio, Inc., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Aphios Corporation, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Araim Pharmaceuticals Inc., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Argos Therapeutics, Inc., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Artery Therapeutics, Inc., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Astellas Pharma Inc., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by AstraZeneca Plc, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Athersys, Inc., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Axxam SpA, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Beta-Cell NV, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Biocon Limited, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Biodel Inc., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Biogenomics Limited, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by BioLineRx, Ltd., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by BioLingus AG, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by BioTherapeutics Inc., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Boehringer Ingelheim GmbH, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Caladrius Biosciences, Inc. , H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Carlina Technologies SAS, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Cellectis S.A., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Compugen Ltd., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Dance Biopharm Inc., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Diabetology (Products) Ltd, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by DiaMedica Inc., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Diasome Pharmaceuticals, Inc., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Dompe Farmaceutici S.p.A., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by DoNatur GmbH, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Effimune SAS, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Eli Lilly and Company, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by enGene, Inc, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by EpiVax, Inc., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Evotec AG, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Fate Therapeutics, Inc., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Generex Biotechnology Corporation, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by GeNeuro SA, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Gilead Sciences, Inc., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by GlaxoSmithKline Plc, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Grifols, S.A., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Halozyme Therapeutics, Inc., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Heptares Therapeutics Limited, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Horizon Pharma Plc, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Iltoo Pharma, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Innopharmax Inc., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by IntelliCell BioSciences Inc., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Intrexon Corporation, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Islet Sciences, Inc., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Johnson & Johnson, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Kadimastem Ltd., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Kamada Ltd., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Kasiak Research Private Limited, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Kineta, Inc., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Lexicon Pharmaceuticals, Inc., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Ligand Pharmaceuticals, Inc., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Lonestar Heart, Inc., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by MacroGenics, Inc., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Medestea Research & Production S.p.A., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by MedImmune, LLC, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Merck & Co., Inc., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Merck KGaA, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Meridigen Biotech Co., Ltd., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Mertiva AB, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by MidaSol Therapeutics LP, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by NatureWise Biotech & Medicals Corporation, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by NOD Pharmaceuticals, Inc., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Novo Nordisk A/S, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Noxxon Pharma AG, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Omni Bio Pharmaceutical Inc., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Oramed Pharmaceuticals, Inc., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Orgenesis, Inc., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Pathfinder Cell Therapy, Inc., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Pfizer Inc., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by PharmaCyte Biotech, Inc., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by PharmaIN Corporation, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Progen Pharmaceuticals Limited, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Prometheon Pharma, LLC, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Provid Pharmaceuticals, Inc., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Purzer Pharmaceutical Co., Ltd., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by RedHill Biopharma Ltd., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by REGiMMUNE Corporation, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Sanofi, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by SEKRIS Biomedical, Inc., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Selecta Biosciences, Inc., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Sevion Therapeutics, Inc., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Strongbridge Biopharma plc , H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Therapix Biosciences Ltd, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Thermalin Diabetes, LLC, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Toleranzia AB, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Transgene Biotek Limited, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Uni-Bio Science Group Ltd., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by United Therapeutics Corporation, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by ViaCyte, Inc., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Visionary Pharmaceuticals, Inc., H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by XL-protein GmbH, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by XOMA Corporation, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) Therapeutics - Recent Pipeline Updates, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Dormant Projects, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Dormant Projects (Contd..1), H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Dormant Projects (Contd..2), H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Dormant Projects (Contd..3), H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Dormant Projects (Contd..4), H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Dormant Projects (Contd..5), H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Dormant Projects (Contd..6), H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Dormant Projects (Contd..7), H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Dormant Projects (Contd..8), H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Dormant Projects (Contd..9), H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Discontinued Products, H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Discontinued Products (Contd..1), H2 2015
  • Type-1 diabetes (Juvenile Diabetes) - Discontinued Products (Contd..2), H2 2015

List of Figures

  • Number of Products under Development for Type-1 diabetes (Juvenile Diabetes), H2 2015
  • Number of Products under Development for Type-1 diabetes (Juvenile Diabetes) - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top